# Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC

> **NCT00647426** · PHASE2 · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 7 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Sorafenib + Docetaxel/Carboplatin

## Key facts

- **NCT ID:** NCT00647426
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2011-08
- **Final completion:** 2012-12
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2019-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00647426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00647426, "Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00647426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*